/PRNewswire/ -- USA News Group News Commentary - Global capital is officially rotating into "Longevity Infrastructure" which is now valued at a massive $27
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 5 of this series includes Hormel Foods, IonQ, Kodiak AI, Lara Exploration and MannKind.
MannKind (MNKD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MannKind Corporation (NASDAQ: MNKD - Get Free Report) insider Stuart Tross sold 47,006 shares of the company's stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $6.33, for a total value of $297,547.98. Following the sale, the insider owned 985,007 shares of the company's stock, valued at $6,235,094.31.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Voya Investment Management LLC cut its holdings in MannKind Corporation (NASDAQ: MNKD) by 89.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 54,871 shares of the biopharmaceutical company's stock after selling 480,182 shares during the period. Voya Investment Management
On Dec. 17, 2025, Michael Castagna, Chief Executive Officer of MannKind Corporation (MNKD +0.00%), executed an exercise and immediate sale of 65,804 common shares for a transaction value of approximately $395,482, according to the SEC Form 4 filing.
FDA approves FUROSCIX ® for use in pediatric patients weighing 43kg or above USPTO issues five patents for FUROSCIX ReadyFlow ™ Autoinjector WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass.
MannKind Corporation (NASDAQ: MNKD - Get Free Report) CEO Michael Castagna sold 65,804 shares of the firm's stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $6.01, for a total value of $395,482.04. Following the completion of the sale, the chief executive officer directly owned 2,504,792 shares in
Virax Biolabs Group (NASDAQ: VRAX - Get Free Report) and MannKind (NASDAQ: MNKD - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Institutional and Insider Ownership 8.6% of Virax
MannKind Corporation delivered strong Q3 '25 results, beating EPS and revenue estimates, and shares have responded positively. The FDA accepted the supplemental New Drug Application for the FUROSCIX ReadyFlow Autoinjector, offering rapid furosemide delivery for CHF and CKD patients. I see a substantial TAM, estimating 670,000 to 1.34 million potential U.S. heart failure patients for ReadyFlow, with significant revenue implications.
If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 seconds Would potentially provide a cost-effective and convenient option to address episodes of fluid buildup at home, benefiting patients, providers and payors PDUFA target action date of July 26, 2026 WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass.
MannKind (NASDAQ: MNKD - Get Free Report) and Silo Pharma (NASDAQ: SILO - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends. Earnings and Valuation This table compares MannKind and
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind Corporation ( MNKD ) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease November 10, 2025 9:00 AM EST Company Participants Michael Castagna - CEO & Director Conference Call Participants Olivia Brayer - Cantor Fitzgerald & Co., Research Division Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Faisal Khurshid - Leerink Partners LLC, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, and welcome to MannKind Corporation's investor call to discuss a clinical trial update.
MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation suspension for nontuberculous mycobacterial (NTM) lung disease, following a futility determination based on medical monitoring data This outcome does not impact the development of MNKD-102, MannKind's dry powder inhalation (DPI) formulation of clofazimine, which remains under consideration for future clinical advancement MannKind extends its sincere gratitude to the study participants, investigators, advisors, and clinical site teams for their invaluable contributions to the ICoN-1 study MannKind will host a conference call today at 9:00 AM EST to discuss this update in more detail DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
$100,000 in scholarship funds to be distributed to at least 10 students living with diabetes pursuing higher education in life sciences Alfred E. Mann Charities and MannKind are partnering with The Diabetes Link to launch the effort in November for Diabetes Awareness Month DANBURY, Conn.
MannKind Corporation ( MNKD ) Q3 2025 Earnings Call November 5, 2025 9:00 AM EST Company Participants Michael Castagna - CEO & Director Christopher Prentiss - Chief Financial Officer Conference Call Participants Olivia Brayer - Cantor Fitzgerald & Co., Research Division Andreas Argyrides - Oppenheimer & Co. Inc., Research Division Yun Zhong - Wedbush Securities Inc., Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Presentation Operator " Michael Castagna CEO & Director " Christopher Prentiss Chief Financial Officer " Olivia Brayer Cantor Fitzgerald & Co., Research Division " Cantor Fitzgerald & Co., Research Division Unknown Analyst " Andreas Argyrides Oppenheimer & Co. Inc., Research Division " Oppenheimer & Co. Inc., Research Division Yun Zhong Wedbush Securities Inc., Research Division " Wedbush Securities Inc., Research Division Brandon Folkes H.C.
Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.